Gastrointestinal Cancer | Specialty

FDA Accepts Resubmission of Lutathera NDA for GEP-NETs

August 29th 2017

The FDA has accepted a resubmitted new drug application for Lutathera (lutetium [177Lu] oxodotreotide) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

An Impactful Year for Molecular Testing in GI Cancers

August 23rd 2017

Antonia R. Sepulveda, MD, PhD, discusses the importance and utility of genetic testing in GI cancers, as well as noteworthy developments in microsatellite instability, BRAF, and KRAS testing in colorectal cancer.

FIT Assay Shows Overall Diagnostic Accuracy for CRC

August 19th 2017

Researchers have concluded from an analysis of multiple studies that the fecal immunochemical test has high overall diagnostic accuracy for screening asymptomatic patients at an increased risk for colorectal cancer (CRC) and moderate accuracy for diagnosing advanced neoplasia (AN).

Clinical Utility of Genetic Testing in CRC Continues to Grow

August 18th 2017

Manuel Hidalgo, MD, discusses his insight on the growth of genetic testing in CRC.

Dr. Modest Discusses the German AIO KRK0110 Study in CRC

August 18th 2017

Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer.

Dr. O'Neil Discusses the Development of Biomarkers for CRC

August 11th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

Dr. Lenz on Need for New Treatment Strategies in Colorectal Cancer

August 11th 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the need for new treatment strategies in colorectal cancer.

Dr. Schmoll on the Objective of CHARTA for CRC

August 10th 2017

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).

Dr. Diaz on Response Rates With Pembrolizumab for CRC

August 3rd 2017

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the response rates of pembrolizumab (Keytruda) for patients with colorectal cancer (CRC).

Biomarker Basics: A Look at MSI's Growing Role

August 2nd 2017

The recent approval of 2 immunotherapies for the treatment of certain patients with tumors that exhibit microsatellite instability has propelled the emerging biomarker into clinical practice, prompting calls for broader genetic testing.

FDA Approves Nivolumab for MSI-H or dMMR Colorectal Cancer

August 1st 2017

The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI Metastases

August 1st 2017

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.

EMA Panel Backs Approval of Lutathera for GEP-NETs

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Lutathera for the treatment of patients with unresectable or metastatic, progressive, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.

Long-Term Imatinib Prevents Recurrence in GIST

July 19th 2017

Patients with intermediate- or high-risk gastrointestinal stromal tumors were less likely to experience recurrence after 5 years of treatment with imatinib (Gleevec), as determined by results from the phase II PERSIST-5 trial.

Napabucasin Combination Shows Early Signs of Activity in Pancreatic Cancer

July 18th 2017

Tanios Bekaii-Saab, MD, discusses the promise of napabucasin in pancreatic cancer.

Prevention Program Targets Pancreatic Cancer Before It Gains a Foothold

July 18th 2017

Pancreatic cancer is currently the fourth-leading cause of cancer death in the United States, with a 5-year survival rate of approximately 8%.

Dr. Hendifar on the Current Treatment Landscape in Pancreas Cancer

July 14th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the current treatment landscape in pancreas cancer.

ODAC Votes to Recommend Approval for Trastuzumab Biosimilar MYL-1401O

July 14th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 to recommend approval to MYL-1401O, the trastuzumab (Herceptin) biosimilar manufactured by Mylan Pharmaceuticals.

HER2 Status in Colorectal Cancer

July 13th 2017

Evidence in BRAF-Mutant CRC Tumors

July 13th 2017